|
ioXell S.p.A. today presents the data from its successful Phase IIb trial of Elocalcitol in BPH (Benign Prostatic Hyperplasia) in a podium presentation at the American Urological Association Annual Meeting (AUA) in Orlando, Florida.
Milan, Italy | May 21, 2008 | BioXell S.p.A. (SWX: BXLN) today presents the data from its successful Phase IIb trial of Elocalcitol in BPH (Benign Prostatic Hyperplasia) in a podium presentation at the American Urological Association Annual Meeting (AUA) in Orlando, Florida.
The key conclusions being presented are that Elocalcitol is effective in improving maximum urinary flow rate (Qmax) and ameliorating lower urinary tract symptoms (LUTS), as well as arresting prostate growth and preventing the risk of Acute Urinary Retention (AUR) and need for surgery, all of which are key parameters of BPH progression. These characteristics, together with an exceptional and placebo-like safety profile, indicate Elocalcitol’s strong potential to become the monotherapy of choice for BPH treatment.
Prof. Francesco Montorsi from the San Raffaele Hospital in Milan (Italy) and lead investigator of the study, who presented the data at the AUA, commented, “The presentation of these results at one of the most renowned international urology conferences is an important step in gaining greater awareness among the urology community of a potential shift in treatment strategy for BPH. Judging from the many oneon- one discussions we have already had regarding Elocalcitol with other experts in the field, we expect a lot of additional interest in these results.”
About BioXell
BioXell (SWX: BXLN) is a biopharmaceutical company focused on the discovery and development of drugs that exploit novel mechanisms of action to treat important urological, inflammatory, and related disorders with significant unmet medical needs. The Company was founded in 2002 as a spin-out from Roche. BioXell's strategic goal is to become a fully integrated pharmaceutical company by maximizing the commercial potential of its product portfolio and leveraging existing platforms into profitable partnerships.
BioXell’s lead compound, Elocalcitol, derived from its proprietary VD3 (Vitamin D3) technology platform, has successfully completed a Phase IIb clinical trial for Benign Prostatic Hyperplasia (BPH). Elocalcitol is currently in a Phase IIb clinical trial for
Overactive Bladder (OAB) and in a Phase II trial for male infertility. In addition, the Company has several follow-on programs based on both VD3 and other technological platforms. These include BXL746, to enter Phase I/II trials for post-surgical adhesions in 2008; MNAC13, an innovative approach to the treatment of pain; and the TREM platform, with TREM-1 in development for the treatment of inflammatory conditions. In June 2006, BioXell listed its shares on the main segment of the SWX Swiss Exchange. BioXell currently employs 58 people and has sites in Milan, Italy and Nutley, NJ, USA. More information on BioXell can be found at: www.bioxell.com
SOURCE: BioXell |
